Clinical Trials

36 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06481735 2026-05-08

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Phase 1/2 Terminated

12 enrolled 15 charts

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04128748 2026-04-24

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

CNSOther hematologic neoplasm

58 enrolled

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

Phase 1/2 Active not recruiting

64 enrolled

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04049539 2026-04-08

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

28 enrolled

Leukemia, Myeloid, Acute

NCT04908111 2026-04-06

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Phase 1/2 Suspended

15 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT03661307 2026-01-12

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

73 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

119 enrolled

Thoracic

Advanced Lung Cancer

NCT06840821 2025-12-02

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

156 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04707300 2025-11-20

HTLP-ONCO

10 enrolled

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT04697940 2025-09-19

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

33 enrolled

Recurrence, Lymphoma, B-Cell

NCT05554939 2025-08-06

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Lymphoma, Non-Hodgkin, Recurrence

NCT06838832 2025-07-30

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Recurrence

NCT07008885 2025-06-25

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07009002 2025-06-25

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Lymphoma, B-Cell

NCT06888830 2025-06-19

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

Phase 1/2 Active not recruiting

374 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumours

NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

15 enrolled 12 charts

DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02257138 2025-06-08

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

30 enrolled 14 charts

Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT06014073 2025-05-25

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Lymphoma, Non-Hodgkin

NCT06323525 2025-05-25

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, Non-Hodgkin

NCT06939270 2025-04-22

CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors

Phase 1/2 Not yet recruiting

Hypoxia

NCT06641453 2024-10-16

CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT06376721 2024-04-19

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

LymphoidOther hematologic neoplasm

43 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04487756 2024-04-03

VENEZO-LUNG

20 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04793399 2024-03-19

Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Phase 1/2 Terminated

9 enrolled 7 charts

Leukemia, Myeloid, Chronic-Phase

NCT04616729 2023-05-18

Depo-Trigger

Helping Behavior

NCT05742750 2023-02-24

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT02652923 2023-01-23

Contrast Ultrasound Detection of Sentinel Lymph Nodes

98 enrolled

Breast

Breast Neoplasms

NCT03709550 2022-10-05

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT04506138 2021-12-14

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

46 enrolled

Esophageal Squamous Cell Carcinoma

NCT03989310 2020-12-23

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

50 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04493099 2020-11-12

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute

NCT03946917 2020-05-12

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

44 enrolled

Colorectal Neoplasms

NCT02921061 2020-03-17

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

28 enrolled 13 charts

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03343665 2020-01-23

Nivo40

Hodgkin Disease

NCT00089284 2019-08-14

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Phase 1/2 Terminated

30 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT04004234 2019-07-09

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

20 enrolled

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT01729845 2019-02-07

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

52 enrolled 9 charts